David J. Moliterno,

David J. Moliterno,'s AcademicInfluence.com Rankings

David J. Moliterno,

Medical

#2035

World Rank

#2429

Historical Rank

Cardiology

#170

World Rank

#175

Historical Rank

medical Degrees

David J. Moliterno,

Philosophy

#5978

World Rank

#8927

Historical Rank

Logic

#3183

World Rank

#4303

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is David J. Moliterno, Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David J. Moliterno,'s Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. (2004) (1024)
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D (2007) (915)
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D (2007) (876)
Incidence (1931) (868)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials (2002) (840)
Third universal definition of myocardial infarction. (2012) (751)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction (1998) (691)
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. (2001) (666)
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (581)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI. (2019) (539)
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study (2013) (532)
ACCF/AHA Expert Conseusus Document (2009) (530)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes (2001) (429)
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. (2016) (406)
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. (1999) (399)
Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction (1997) (387)
Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D (2007) (381)
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. (1998) (367)
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study (2001) (360)
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina (1998) (351)
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. (2006) (321)
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. (2019) (302)
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study (2009) (292)
Single Nucleotide Polymorphisms in Multiple Novel Thrombospondin Genes May Be Associated With Familial Premature Myocardial Infarction (2001) (287)
Increased mortality among patients taking digoxin--analysis from the AFFIRM study. (2013) (269)
Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. (1994) (268)
Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention (2002) (261)
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials (2001) (237)
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy (2001) (233)
Premature myocardial infarction novel susceptibility locus on chromosome 1P34-36 identified by genomewide linkage analysis. (2004) (232)
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2008) (223)
Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting (2011) (222)
Subacute stent thrombosis: evolving issues and current concepts. (1996) (219)
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. (1998) (212)
Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. (2003) (211)
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. (2000) (211)
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study (2000) (193)
Prognostic significance of elevated troponin I after percutaneous coronary intervention. (2002) (183)
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (179)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials ☆ (2002) (177)
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. (2018) (172)
Non-invasive assessment of plaque morphology and remodeling in mildly stenotic coronary segments: comparison of 16-slice computed tomography and intravascular ultrasound (2003) (171)
2012 American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: A report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in co (2012) (165)
Alleviation of cocaine-induced coronary vasoconstriction by nitroglycerin. (1991) (163)
Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention (2004) (162)
In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. (2009) (161)
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. (2001) (161)
Influence of labetalol on cocaine-induced coronary vasoconstriction in humans. (1993) (156)
Combining antiplatelet and anticoagulant therapies. (2009) (156)
The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. (2006) (155)
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. (2002) (152)
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. (1995) (149)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes (2002) (144)
Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes (2002) (144)
The Role of the Platelet in the Pathogenesis of Atherothrombosis (2005) (142)
Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association With Clinical Outcome in Patients Undergoing Coronary Stenting (2004) (138)
The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). (2005) (138)
Influence of intranasal cocaine on plasma constituents associated with endogenous thrombosis and thrombolysis. (1994) (136)
Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes (2004) (135)
No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. (1995) (129)
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography. (2009) (129)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
G-Protein–Coupled Receptors as Signaling Targets for Antiplatelet Therapy (2009) (125)
Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention. (1999) (124)
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society (2012) (123)
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting: A North American Perspective: Executive Summary (2011) (119)
Differences between men and women in the management of unstable angina pectoris (The GUARANTEE Registry). The GUARANTEE Investigators. (1999) (115)
ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography (2010) (115)
In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? (2007) (114)
First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. (1997) (113)
Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. (2010) (113)
Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. (2002) (110)
Evidence for substantial effect modification by gender in a large-scale genetic association study of the metabolic syndrome among coronary heart disease patients (2003) (107)
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. (2004) (107)
Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival (2003) (106)
Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention: Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up (2002) (103)
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. (2008) (98)
Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. (1997) (96)
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes (2002) (92)
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study (2002) (90)
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. (2016) (89)
Hemodynamic effects of intranasal cocaine in humans. (1992) (83)
Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* (2002) (83)
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes (2014) (82)
Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. (1993) (80)
The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. (1998) (79)
Stent thrombosis. (2010) (79)
Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. (2000) (77)
Early statin initiation and outcomes in patients with acute coronary syndromes. (2002) (76)
Renal function, concomitant medication use and outcomes following acute coronary syndromes. (2005) (75)
Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. (2006) (75)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. (2000) (73)
A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. (2000) (72)
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). (2003) (72)
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old. (2003) (72)
Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction: Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial (2000) (70)
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. (2020) (65)
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. (2002) (64)
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. (2021) (61)
The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. (2002) (58)
Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease (2003) (58)
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes (1999) (57)
Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. (2008) (57)
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (2004) (55)
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
Contemporary use of glycoprotein IIb/IIIa inhibitors (2012) (54)
Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. (2004) (51)
The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. (2005) (51)
Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". (2000) (49)
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). (2002) (48)
A randomized two‐by‐two comparison of high‐dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: The tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TE (2011) (47)
Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. (2016) (47)
Restenosis—an open file (1996) (47)
Triple antiplatelet therapy does not increase femoral access bleeding with vascular closure devices. (2003) (47)
Patient-specific dosing of IIb/IIIa antagonists during acute coronary syndromes: rationale and design of the PARAGON B study. The PARAGON B International Steering Committee. (2000) (47)
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. (2000) (46)
Inside-out access: a new method of lead placement for patients with central venous occlusions. (2010) (45)
Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. (2009) (44)
Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. (2004) (43)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). (2014) (43)
2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement (2012) (42)
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. (2013) (42)
A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. (2003) (42)
Real‐world bare metal stenting: Identification of patients at low or very low risk of 9‐month coronary revascularization (2004) (41)
Achieving tissue-level perfusion in the setting of acute myocardial infarction. (2000) (41)
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
Coronary intravascular ultrasound: diagnostic and interventional applications. (1995) (40)
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era. (2006) (39)
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE registry (1998) (39)
A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study. (2000) (38)
Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. (2003) (38)
Racial differences in the management of unstable angina: results from the multicenter GUARANTEE registry. (1999) (38)
Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. (2003) (37)
International variation in invasive care of the elderly with acute coronary syndromes. (2006) (37)
Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations (2012) (37)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
&bgr;-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise (2001) (37)
Expert Consensus Document Accf/acr/aha/nasci/scmr 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Writing Committee Members Expert Consensus Document Table of Contents Hundley Et Al (2010) (36)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction. (2012) (35)
Conjunctive Use of Platelet Glycoprotein IIb/IIIa Antagonists and Thrombolytic Therapy for Acute Myocardial Infarction (1997) (35)
Safety and efficacy of protease‐activated receptor‐1 antagonists in patients with coronary artery disease: a meta‐analysis of randomized clinical trials (2012) (35)
Identification, Diagnosis and Treatment of Heparin-induced Thrombocytopenia and Thrombosis: A Registry of Prolonged Heparin Use and Thrombocytopenia among Hospitalized Patients with and without Cardiovascular Disease (2005) (35)
Insights into the pathophysiology of atherosclerosis and prognosis of black Americans with acute coronary syndromes. (1999) (34)
Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and Discontinuation (2003) (34)
Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. (2013) (33)
Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years (2015) (33)
Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. (2016) (33)
Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites. (2008) (32)
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial. (2003) (30)
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. (2021) (28)
Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. (2002) (28)
Resistance to antiplatelet resistance is it justified? (2005) (28)
Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes (2014) (27)
Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. (2003) (27)
Glycoprotein IIb/IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. (2003) (27)
More Complete and Stable Reperfusion with Platelet IIb/IIIa Antagonism Plus Thrombolysis for AMI: The PARADIGM Trial (1996) (27)
Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial (2012) (26)
Closure devices and vascular complications among percutaneous coronary intervention patients receiving enoxaparin, glycoprotein IIb/IIIa inhibitors, and clopidogrel (2005) (26)
Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. (2005) (25)
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. (2004) (24)
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
Outcomes in African Americans and whites after percutaneous coronary intervention. (2005) (23)
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups (2006) (23)
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry) (2017) (23)
Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. (2002) (23)
Platelet Glycoprotein IIb/IIIa Receptor Antagonists And Their Use In Elderly Patients (2000) (22)
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) (2018) (21)
Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER (2014) (20)
Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second‐generation drug‐eluting stents for coronary artery disease: A systematic review and meta‐analysis of randomized trials (2016) (20)
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. (2005) (20)
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
Is There an Association Between External Cardioversions and Long-Term Mortality and Morbidity?: Insights From the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Study (2011) (20)
The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice (2006) (20)
Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment (2005) (18)
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. (2014) (18)
QRS duration predicts death and hospitalization among patients with atrial fibrillation irrespective of heart failure: evidence from the AFFIRM study. (2014) (18)
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). (2015) (18)
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact (2015) (18)
Clopidogrel for percutaneous coronary revascularization: time for more pretreatment, retreatment, or both? (2005) (18)
Heparin-induced thrombocytopenia and cardiovascular diseases. (2006) (17)
Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry (2019) (17)
Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. (2003) (17)
Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. (2017) (17)
Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). (2018) (16)
Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. (2021) (16)
Randomized trials of myocardial revascularization. (1995) (16)
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. (2006) (16)
Effectiveness of PCI for non-acute coronary artery disease (2009) (16)
Cardiovascular Catheterization and Intervention: A Textbook of Coronary, Peripheral and Structural Heart Disease. (2010) (16)
Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. (2003) (16)
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial (2012) (15)
Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial (2014) (15)
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. (2021) (15)
Second-generation drug-eluting stents and the continuous need for rapidly available real-world data. (2009) (15)
Troponins in acute coronary syndromes: More TACTICS for an early invasive strategy. (2001) (15)
2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons so (2012) (15)
2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons so (2012) (15)
The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. (1998) (14)
Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?) (2007) (14)
Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT. (2001) (14)
Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention (2020) (14)
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial. (2003) (14)
Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. (2016) (13)
Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy (2016) (13)
Optimal Activated Clotting Time During Percutaneous Coronary Intervention (2001) (13)
Delaying and Preventing Ischemic Events in Patients with Acute Coronary Syndromes Using the Platelet Glycoprotein IIb/IIIa Inhibitor Lamifiban (1997) (13)
Brachytherapy for in-stent restenosis: a distant second choice to drug-eluting stent placement. (2006) (13)
Are we appropriately triaging patients with unstable angina? (2005) (13)
Defining the role of abciximab for acute coronary syndromes: Lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET (2001) (13)
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry (2016) (13)
Prognostic importance of physical examination for heart failure in non-St-elevation acute coronary syndromes the enduring value of Killip classification (2004) (13)
Influence of insurance type on the use of procedures, medications and hospital outcome in patients with unstable angina: results from the GUARANTEE Registry. Global Unstable Angina Registry and Treatment Evaluation. (1998) (13)
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention: Insights From the PARIS Registry (2019) (12)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
In-stent restenosis: update on intracoronary radiotherapy. (2001) (12)
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial (2018) (12)
Drug-drug interactions in cardiovascular catheterizations and interventions. (2012) (12)
Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). (2009) (12)
Effectiveness of drug-eluting stents in real-world patients. (2008) (12)
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. (2019) (11)
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (2018) (11)
Monitoring Antiplatelet Therapy (2000) (11)
Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. (2010) (11)
Stenting for acute myocardial infarction: The early United States multicenter experience (1996) (11)
An Automated Strategy for Bedside aPTT Determination and Unfractionated Heparin Infusion Adjustment in Acute Coronary Syndromes: Insights from PARAGON A (2002) (11)
Optimal platelet inhibition in patients undergoing PCI: data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. (2007) (11)
Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. (2017) (10)
Lamifiban. Point of view (1999) (10)
Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin? (2019) (10)
Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. (2002) (10)
Surgical restoration of antegrade flow in the occluded infarct artery improves long‐term survival in patients with multivessel coronary artery disease (1993) (10)
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). (2017) (10)
Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery (2015) (10)
Peripartum myocardial infarction. (1993) (10)
Association of genetic variants in the HDL receptor , SRB 1 , with abnormal lipids in women with coronary artery disease (2003) (10)
Present and potential future paradigms for the treatment of ST-segment elevation acute myocardial infarction. (2002) (9)
TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL (2016) (9)
Platelet glycoprotein IIb/IIIa receptor antagonists (2000) (9)
Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. (2017) (9)
Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. (2000) (8)
1100-59 High-dose clopidogrel loading rapidly reduces both platelet inflammatory marker expression and aggregation (2004) (8)
Unraveling questions surrounding clopidogrel resistance and stent thrombosis: one less snag. (2007) (8)
Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial (1998) (8)
Unexpected mortality reduction with abciximab for in-stent restenosis. (2000) (8)
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. (2021) (8)
Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. (2018) (8)
Fractionating heparins and their clinical trial data--something for everyone. (2004) (8)
Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. (2009) (8)
Glycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarction. (2002) (7)
Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. (2009) (7)
Restenosis following thin‐strut bare‐metal stents versus thick‐strut drug‐eluting stents (2007) (7)
The Evolving Role of Cardiac Troponin in the Evaluation of Cardiac Disorders (2013) (7)
Bifurcation stenting techniques and outcomes in patients with stable coronary artery disease: more evidence suggesting simpler is safer. (2015) (7)
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. (2003) (7)
Advances in antiplatelet therapy for ACS and PCI. (2008) (7)
Relationship of Outcomes to Treatment with Lamifiban in Patients Undergoing PTCA: Analysis of PARAGON A (1997) (7)
Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. (2019) (7)
Clopidogrel pretreatment prior to percutaneous coronary intervention attenuates periprocedural rise of C-reactive protein (2003) (7)
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients. (2004) (7)
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar (2016) (7)
730-3 “Directional” Coronary Atherectomy Removes Atheroma More Effectively from Concentric than Eccentric Lesions: Intravascular Ultrasound Predictors of Lesional Success (1995) (6)
CYP2C19 Genotyping to Guide Antiplatelet Therapy After Percutaneous Coronary Interventions: One Size Rarely Fits All. (2020) (6)
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (2016) (6)
Abstract 14508: Vorapaxar for Secondary Prevention after Myocardial Infarction According to Aspirin Dose - Insights from the TRA2{degrees}P-TIMI 50 Trial (2012) (6)
A Major Dichotomy in Unstable Angina Outcome : ST Depression Versus T-Wave Inversion : GUSTO-II Results (1996) (6)
Abstract 19049: Net Clinical Benefit of Vorapaxar in NSTE ACS: Role of Ischemic and Bleeding Risk Stratification (2012) (6)
Diabetes and percutaneous coronary intervention: the sweet smell of success? (2003) (6)
Assessing the effect of publication of clinical guidelines on the management of unstable angina and non-ST elevation myocardial infarction in the TIMI III (1990-1993) and the GUARANTEE (1995-1996) Registries. (2002) (6)
Late diverging event curves for survival following IIb/IIIa antagonism in patients with unstable angina: PARAGON study 1-year follow-up (1998) (6)
Potential hazards of adding nonsteroidal anti-inflammatory drugs to antithrombotic therapy after myocardial infarction: time for more than a gut check. (2015) (6)
Clinical Application of Procedural Platelet Monitoring during Percutaneous Coronary Intervention among Patients at Increased Bleeding Risk (2001) (6)
The platelet function dose‐response to abciximab during percutaneous coronary revascularization is variable (2001) (6)
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk: A Cost Consequence Simulation From PARIS (2019) (6)
The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. (2008) (6)
Angioplasty, inflammation, and antiplatelet agents. (2003) (6)
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review. (2020) (6)
Left main dissection and thrombosis in a young athlete. (2005) (6)
Sunday, 26 August 2012 (2012) (5)
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study. (2021) (5)
Expert Consensus Document Accf/acr/aha/nasci/saip/scai/scct 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents Writing Committee Members Expert Consensus Document Table of Cont (5)
The TARGET trial: hit or miss? (2002) (5)
Plasma concentration of lamifiban and glycoprotein IIb-IIIa receptor occupancy best predict clinical outcome in patients with unstable angina: results from PARAGON A (1998) (5)
Association of race with complications and prognosis following acute coronary syndromes. (2004) (5)
American College of Cardiology Annual Scientific Session 2010: update in interventional cardiology. (2010) (5)
President's page: drug-eluting stents in contemporary practice--a call for a real-world, open-entry, device-tracking registry. (2007) (5)
Role of cardiac computed tomography and magnetic resonance imaging in the evaluation of acute chest pain in the emergency department (2008) (5)
Discharge timing and outcomes after uncomplicated non–ST‐segment elevation acute myocardial infarction (2018) (5)
Contemporary use of antiplatelet therapies in percutaneous coronary interventions (2003) (5)
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI (2022) (4)
Applications of Anti-Platelet Monitoring in Catheterization Laboratory (2000) (4)
Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial (1998) (4)
Is there an Association Between External Cardioversions and Long Term Mortality and Morbidity - Insights from the AFFIRM Study (2011) (4)
Another step toward resolving the contrast controversy. (1996) (4)
Bare-metal versus drug-eluting stent placement among patients presenting with anemia. (2009) (4)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. (2002) (4)
Platelet protease-activated receptor antagonism in cardiovascular medicine. (2012) (4)
Unfortunate impact of age on the management and outcomes of unstable angina and non-ST elevation myocardial infarction (The GUARANTEE Registry). (2005) (4)
Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study (1995) (4)
Glycoprotein IIb/IIIa receptor antagonists for the treatment of unstable angina. (1997) (4)
New Anticoagulants in Ischemic Heart Disease (2012) (3)
Diabetes and coronary revascularization: defining optimal revascularization modality and adjunctive medical treatment (2004) (3)
Unstable Angina: PARAGON, PURSUIT, PRISM, and PRISM-PLUS (1999) (3)
Revascularisation for patients with stable coronary artery disease (2014) (3)
New Electrocardiographic Criteria for Identifying the Culprit Artery in Inferior Wall Acute Myocardial Infarction—Usefulness of T-Wave Amplitude Ratio in Leads II/III and T-Wave Polarity in the Right V 5 Lead (2004) (3)
Combining IIb/IIIa Inhibition and Heparin for Acute Coronary Syndromes: Evidence of a Gradient for Bleeding Hazard from the PARAGON Randomized Factorially Designed Trial (1997) (3)
Bedside activated partial thromboplastin time monitoring: just a matter of time? (1999) (3)
Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry (2019) (3)
711-4 Low Plasma Homocysteine Levels Predict Reduced Atheroma Burden in Patients Undergoing Coronary Interventions: Evidence from Intravascular Ultrasound (1995) (3)
Cardiovascular Catheterization and Intervention : A Textbook of Coronary, Peripheral, and Structural Heart Disease, Second Edition (2017) (3)
Glycoprotein IIb/IIIa Combination Therapy in Acute Myocardial Infarction: Tailoring Therapies to Optimize Outcome (2002) (3)
Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS? (2011) (3)
EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL (2013) (3)
Amplification of clinical benefit at six months with the glycoprotein IIb/IIIa inhibitor lamifiban in patients with non ST segment elevation in acute coronary syndromes (1997) (3)
Enoxaparin in Clinical Practice and Clinical Trials of Non-ST-Elevation Acute Coronary Syndrome (NSTE-ACS) (2005) (3)
Patient, Heal Thyself: The Ongoing Evolution of Patient Self-directed Care and Hand-Held Technology (2011) (3)
Tissue necrosis factor α and targeting its receptor in ischaemic heart disease (2013) (3)
State-of-the-Art Papers: Gemstones. (2018) (3)
Antiplatelet polypharmacy in primary percutaneous coronary intervention: trying to understand when more is better. (2009) (3)
935-34 Special Considerations for Diabetics Receiving Platelet IIb/IIIa Antagonists During Coronary Interventions: Results from the EPIC Trialart (1995) (3)
Platelet glycoprotein IIb/IIIa antagonists are beneficial in patients with acute coronary syndromes who undergo in-hospital coronary artery bypass surgery (2003) (2)
Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial (2012) (2)
JACC: Cardiovascular Interventions 2.0: The Journey Begins. (2017) (2)
CT Angiography for Emergency Decision Making in Acute Coronary Syndromes: Applying Future Vision Now (2012) (2)
WHITE BLOOD CELL COUNT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS AFTER PERCUTANEOUS CORONARY INTERVENTION IN THE CONTEMPORARY ERA: INSIGHTS FROM THE PARIS STUDY (2017) (2)
Point of care testing for aPTT improves cost outcomes following coronary intervention (1998) (2)
Differences Between Unstable Angina and Acute Myocardial Infarction: Pathophysiological and Clinical Spectrum (2004) (2)
Plasma lipoprotein(a) concentrations are not elevated by cardiopulmonary bypass. (1993) (2)
More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents: Related Versus Unrelated Events. (2017) (2)
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. (2005) (2)
Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial (2017) (2)
CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
Diabetes doubles the risk of death among patients presenting with acute coronary syndromes: insights from SYMPHONY, a large international trial (2001) (2)
ASSOCIATION OF STENT THROMBOSIS AND PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS: SIX MONTH RESULTS OF THE PARIS REGISTRY (2012) (2)
1138-43 Relationship of obesity to target vessel revascularization and other outcomes following coronary stenting: Observations from the TARGET trial (2004) (2)
Abstracts - ACCIS2002 (angiography & interventional cardiology)Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial (2002) (2)
Rotational atherectomy for resistant chronic total occlusions: Another spin for tough old problems (2010) (2)
Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease : Results From TRACER (2013) (2)
The Top Papers of 2017: By Subsequent Citations and Online Views and Downloads. (2018) (2)
Long-term follow-up of drug-eluting stents placed in the setting of ST-segment elevation myocardial infarction. (2011) (2)
Abstract 3071: Meta-Analysis of High-Dose Single-Bolus Tirofiban versus Abciximab in Patients Undergoing Percutaneous Coronary Interventions (2006) (2)
Bedside Platelet Monitoring (2004) (2)
Research Correspondence: One Good Point, One Great Figure (or Table). (2017) (2)
Giant saphenous vein graft aneurysm. (2002) (1)
A new rapid ecarin clotting time assay but not activated clotting time strongly correlates with bivalirudin concentration: a percutaneous coronary intervention study (2002) (1)
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. (2022) (1)
Point-of-care measurement of platelet function before angioplasty strongly predicts future target vessel revascularization (2002) (1)
JACC Journals' Pathway Forward With AI Tools: The Future Is Now. (2023) (1)
Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome : Insights From the TRACER Trial (2013) (1)
Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspective. (1999) (1)
Editorial: protein C and S deficiency as a risk factor for stent thrombosis--when a rare disorder can predispose to rare events. (2010) (1)
Contemporary occurrence of stent thrombosis in clinical practice: Better never than late (2012) (1)
Combination therapy: management of acute myocardial infarction in the new millennium. (2000) (1)
Bedside Anticoagulant Testing (2004) (1)
CTO-Chronic Total Occlusions and Continuous Training Opportunity. (2017) (1)
Reduction in recurrent ischemic events with vorapaxar: results from TRACER (2013) (1)
1123-180 Incidence and evaluation of heparin-induced thrombocytopenia (HIT) among patients treated with prolonged heparin and among thrombocytopenic patients in the cardiac care unit: Preliminary results of the CATCH registry (2004) (1)
Ageless benefits of transradial access for percutaneous coronary revascularization (2015) (1)
Glycoprotein IIb/IIIa Inhibitors (2010) (1)
Diabetes is an independent predictor of increased mortality following contemporary percutaneous coronary intervention for proximal left anterior descending artery disease (2003) (1)
Hybrid coronary revascularization: Time for a new comparator? (2018) (1)
Liposomal PGE-1 adjunctive treatment for acute myocardial infarction: final results of the LIFT pilot trial (1998) (1)
Did we enjoy the debate but forget the patient? (2004) (1)
The Timely Coupling of Mechanical Revascularization following Thrombolysis for Myocardial Infarction (2007) (1)
Timing and risk factors for enzymatic myocardial infarctions in patients undergoing percutaneous intervention: Insights from TARGET (2003) (1)
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. (2022) (1)
Chapter 13 – Restenosis and in-stent restenosis (2008) (1)
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age (1)
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us. (2001) (1)
Invasive vs conservative management of non-Q-wave myocardial infarction. (1999) (1)
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. (2022) (1)
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes. (2014) (1)
“Hot” Unstable Angina—Is it Worse than Subacute Unstable Angina? Results from the GUARANTEE Registry (2001) (1)
Being a Great Reviewer: Remembering the "Why". (2018) (1)
PATTERNS OF ADHERENCE TO DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE UNDERGOING COMPLEX PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE PARIS REGISTRY (2015) (1)
The Evolution of a Department of Internal Medicine Under an Integrated Clinical Enterprise Model: The University of Kentucky Experience (2010) (1)
A randomized multicenter trial comparing a new, low-pressure versus a conventional coronary stent: primary results from the CONSERVE trial. (2003) (1)
The Use of Drug-Eluting Stents Versus Bypass Surgery for Left Main Coronary Artery Disease (2011) (1)
The Case for Mandatory COVID-19 Vaccination of Health Care Workers (2021) (1)
Clinical characteristics associated with major bleeding in NSTE ACS and the relationship between bleeding risk, ischemic events, and the vorapaxar effect : analysis from the TRACER trial (2012) (1)
Glycoprotein IIb/IIIa Antagonists (2017) (1)
Thrombolytic therapy for acute myocardial infarction (2001) (1)
The ST-Depression >=2 mm sign: an ominous prognosis in acute coronary syndromes (1999) (1)
Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention (2006) (0)
ASSOCIATIONS BETWEEN DIFFERENT MODES OF DAPT CESSATION AND MAJOR ADVERSE EVENTS AT 6 MONTHS AND BEYOND: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study (2022) (0)
TCT-501 Dual Antiplatelet Therapy Interruption For Surgery: Insights From The PARIS (Patterns Of Non-adherence To Anti-Platelet Regiments In Stented Patients) Registry (2014) (0)
Left main and multivessel coronary artery stenting for patients deemed inoperable—A real need for a tandem approach (2009) (0)
JACC Journals' Pathway Forward With AI Tools: The Future Is Now. (2023) (0)
Improved outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery treated with combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition (2002) (0)
The Year of Special Anniversaries: Tin, Crystal, Silver, and Ruby. (2017) (0)
Vessel Overlap, Foreshortening, and Ostial Lesions (2010) (0)
Renal insufficiency and its relation to ischemic and bleeding outcomes with tirofiban versus abciximab in the TARGET trial (2002) (0)
PotentialHazardsofAddingNonsteroidalAnti-inflammatoryDrugs toAntithromboticTherapyAfterMyocardial Infarction Time for More Than a Gut Check (2015) (0)
Unstable Angina Trials: PARAGON, PURSUIT, PRISM, PRISM-PLUS, and GUSTO-IV (2003) (0)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA center dot CER) Trial (2011) (0)
INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL (2013) (0)
Contents Vol. 107, 2007 (2006) (0)
PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL (2012) (0)
Creating biodegradable‐polymer drug‐eluting stents: Shortening the duration of polymer and dual antiplatelet therapy while lengthening the follow‐up (2012) (0)
The Value of Focus. (2017) (0)
Be Careful What You Read and the Company You Keep. (2017) (0)
TCT-219 Influence Of Anemia On Physician-Recommended DAPT Discontinuation After Percutaneous Coronary Intervention. (2016) (0)
A Letter to the (Founding) Editor: A King by Any Name. (2017) (0)
JACC Journals' Pathway Forward With AI Tools: The Future Is Now. (2023) (0)
Carotid and vertebral artery interventions (2010) (0)
The Use of Single Versus Dual Antiplatelet Therapy Beyond 1 Year Following Drug-Eluting Stent Implantation (2010) (0)
Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial (2014) (0)
Cardiac amyloidosis. (2008) (0)
Reassessing Patients Over Time : How To Follow Patients on Treatment (2009) (0)
Optimization of glycoprotein IIb/IIIa blockade during percutaneous coronary interventions: Insights from target after 1 year (2003) (0)
Full Issue PDF (2020) (0)
Finding sideline benefits—Of pandemics and same‐day‐discharge following rotational atherectomy (2021) (0)
Post-exercise left ventricular end systolic volume is correlated with end systolic elastance and preload recruitable stroke work relationship in mitral regurgitation (2003) (0)
Managing unstable angina in high-risk patients. (2002) (0)
918-21 Intravascular Ultrasound Evidence of Significant Oversizing of Angioplasty Balloons in Female Patients (1995) (0)
Zotarolimus‐eluting stents among patients with renal impairment undergoing percutaneous coronary intervention (2012) (0)
Therapeutic strategies in thrombosis (2013) (0)
Thrombocytopenia Is More Common and Nadir Occurs Earlier with Unfractionated Heparin Than with Low Molecular Weight Heparin - Results from the Prospective Catch Registry. (2004) (0)
Coronary interventions among patients with hepatic insufficiency: Encouragement to avoid a jaundiced view (2020) (0)
Acute ischemic stroke and the acute need for expansion of stroke teams and their membership (2021) (0)
Late target lesion revascularization following drug‐eluting stents—looking back and forward to success (2008) (0)
Emerging Treatment of Acute Coronary Syndromes with Platelet Glycoprotein IIB/IIIA Inhibitors (1999) (0)
Measurement of Cardiac Output (2010) (0)
Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction : Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome ( TRACER ) (2017) (0)
TARGET follow-up study. Authors' reply (2002) (0)
Events) Registry Report From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Patients With Chronic Kidney Disease in the Era of Drug-Eluting Stents: A In-Hospital and 1-Year Outcomes Among Percutaneous Coronary Intervention (2011) (0)
784-4 Older Donor Age Predicts Increased Risk for Coronary Vasculopathy in the Year Following Transplantation: Serial Examination by Intravascular Ultrasound (1995) (0)
TEMPORAL TRENDS OVER 15 YEARS IN CLINICAL TRIALS OF NON-ST ELEVATION ACUTE CORONARY SYNDROMES: MORE AGGRESSIVE TREATMENT YIELDS SIMILAR MORTALITY DESPITE HIGHER-RISK PROFILES (2010) (0)
age subgroups coronary syndromes: Benefit and harm in different blockers in non-ST-segment elevation acute Effects of platelet glycoprotein IIb/IIIa receptor (2008) (0)
TCT CONNECT-64 Impact of DAPT Cessation in High Bleeding-Risk Patients Undergoing PCI: Insights From the PARIS Registry (2020) (0)
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of glassy and twilight. (2023) (0)
TEMPORAL ASSOCIATIONS BETWEEN TIME AFTER PERCUTANEOUS CORONARY INTERVENTION, DUAL ANTIPLATELET THERAPY CESSATION AND STENT THROMBOSIS IN THE CONTEMPORARY PCI ERA: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Full Issue PDF (2020) (0)
Racial differences in outcome following percutaneous coronary intervention (2008) (0)
Valves in the Heart of the Big Apple V: Evaluation and Management of Valvular Heart Diseases 2007.Third Annual Scientific Session: Heart Valve Society of America, New York City, N.Y., April 12–14, 2007 (2007) (0)
Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial (2013) (0)
Vasopressors, Vasodilators, and Antithromboticsin The Catheterization Laboratory (2017) (0)
High‐Dose Tirofiban (2009) (0)
Large-Scale CAS Registries (2010) (0)
IMPACT OF AGE ON THE MODES OF DUAL ANTIPLATELET THERAPY CESSATION: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2015) (0)
Lamifiban: A Viewpoint by David J. Moliterno (1999) (0)
TCT-110 Incidence, predictors, and outcomes of DAPT disruption due to non-compliance versus bleeding after PCI: insights from the PARIS Registry (2018) (0)
ANGIOGRAPHIC TECHNIQUE Arterial Access (2010) (0)
Year 1: A Short Look Back and a Long Look Forward. (2018) (0)
Images in Intervention: Icons. (2018) (0)
TCT-13 Ticagrelor Monotherapy in Patients With Peripheral Artery Disease Undergoing PCI (2022) (0)
Evolving our learning and application of knowledge to practice—The ongoing challenges of time and cost in interventional cardiology (2022) (0)
Abstract 16787: Use of Thienopyridine Prior to Presentation for Acute Coronary Syndromes and Association With Safety and Efficacy of Vorapaxar: Insights From the TRACER Study (2014) (0)
Abstract 17468: Is There an Association Between Number of External Cardioversions and Mortality_Insights from the AFFIRM Study (2010) (0)
TCT-206 Tailoring the Intensity of Antiplatelet Pharmacotherapy to Ischemic and Bleeding Risk: A Cost Optimizing Simulation From PARIS. (2016) (0)
Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials (2001) (0)
JACC Journals’ Pathway Forward With AI Tools (2023) (0)
Abstract 15834: Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years (2013) (0)
Late drug-eluting stent thrombosis in unprotected left main coronary artery lesions--sometimes possible, but rarely definite or probable. (2008) (0)
Abstract 15659: Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Non-ST-Segment Elevation Acute Coronary Syndrome Patients in TRACER (2012) (0)
Intravascular ultrasound evidence for balloon oversizing in diabetics: A factor in higher complication rates? (1996) (0)
INCREASED MORBIDITY AND MORTALITY AMONG ATRIAL FIBRILLATION PATIENTS WITH PROLONGED QRS: RESULTS FROM THE AFFIRM STUDY (2012) (0)
Abstract 84: Impact of Education on Dual Antiplatelet Therapy Adherence (2012) (0)
Prolongation of Activated Clotting Time (ACT) With Tirofiban Versus Abciximab and Its Association to Outcome: Results From TARGET (2002) (0)
Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: new therapeutic regimen for acute myocardial infarction. (2000) (0)
JACC Journals' Pathway Forward With AI Tools: The Future Is Now. (2023) (0)
JACC Journals' Pathway Forward With AI Tools: The Future Is Now. (2023) (0)
Platelet ADP P2Y12 Inhibitors: Nonthienopyridines (2012) (0)
Trifurcation left main coronary artery percutaneous revascularization—Pushing catheters and envelopes (2009) (0)
JACC Journals’ Pathway Forward With AI Tools (2023) (0)
Acute Coronary Syndromes Compendium Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes (2014) (0)
DUAL ANTIPLATELET THERAPY (DAPT) CESSATION AND CARDIOVASCULAR RISK IN RELATION TO AGE: ANALYSIS FROM THE PARIS (PATTERNS OF NON-ADHERENCE TO ANTI-PLATELET REGIMENS IN STENTED PATIENTS) REGISTRY (2019) (0)
Patterns of dual anti platelet therapy cessation in left main and proximal left anterior descending artery PCI: Results from the PARIS registry (2015) (0)
TCT-205 Incidence and clinical outcomes associated with DAPT discontinuation in complex PCI patients: From the PARIS registry. (2016) (0)
Acute Coronary Syndromes PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRA·CER TRIAL (2012) (0)
Improvements in the treatmant of elderly patients with unstable angina results from the GUARANTEE registry (1998) (0)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes Clinical Investigation and Reports (2001) (0)
Imminent extinction of brachy(saurus)therapy for the treatment of in‐stent restenosis (2006) (0)
FREQUENCY AND IMPACT OF SINGLE VERSUS DUAL ANTIPLATELET CESSATION ON ADVERSE CARDIAC EVENTS: RESULTS FROM THE PARIS REGISTRY (2013) (0)
Abstract 13080: Drug-Eluting Stents Versus Bare-Metal Stents in Primary Percutaneous Coronary Interventions is Efficacious And Safe for Long Term Outcomes in ST-Segment Elevation Myocardial Infarction. A Systematic Review and Meta-Analysis (2011) (0)
Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention. (2009) (0)
DES Update 2010 (2010) (0)
TCT-39 Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index: TWILIGHT-BMI Analysis (2021) (0)
Immediate vs Delayed Coronary Angiography for Out-of-Hospital Cardiac Arrest: A Meta-Analysis of Randomized Controlled Trials. (2023) (0)
OralBleeding and the Hazards of AnticoagulationTCT-89 Tradeoff between Myocardial Infarction and Bleeding in Relation to Bleeding Risk: insights from PARIS registry (2017) (0)
TCT-225 Impact of Age on the Disruption of Dual Antiplatelet Therapy: Analysis from the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented) Patients Registry (2015) (0)
Increased doses of clopidogrel or aspirin did not prevent cardiovascular events (2011) (0)
Coronary heart disease Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes (2006) (0)
Little Kids, Little Problems-Big Kids, Big Problems. (2017) (0)
unfractionated versus low‐molecular‐weight heparin for primary angioplasty—More data suggesting to go low (2011) (0)
The Top Papers of 2017: Editor's Pick. (2018) (0)
PREDICTORS OF DUAL ANTIPLATELET THERAPY NON-ADHERENCE AFTER PCI: ONE-YEAR INSIGHTS FROM THE PARIS REGISTRY (2013) (0)
Are tirofiban and abciximab identical in efficacy?: reply (2005) (0)
Early and late outcome associated with bleeding events in the setting of dual antiplatelet therapy following stent placement (2012) (0)
Abstract 16705: Lower Education Level is Associated with Non-Adherence to Dual Antiplatelet Therapy After PCI: 6-Month Results from PARIS (2012) (0)
Remote ischemic preconditioning in elective percutaneous coronary intervention does not protect myocardium nor mobilize endothelial progenitor cells (2013) (0)
Abstract 18402: Impact of the Use of Different Bleeding Scales on the Rate of 6-Month Bleeding After PCI: Results from the PARIS Registry (2012) (0)
Abstract 14419: Natural History of Atherothrombotic Events According to the Primary Diseased Vascular Bed - Insights from the TRA2P-TIMI 50 Trial (2012) (0)
Prasugrel versus clopidogrel in primary PCI: Considerations of the TRITON-TIMI 38 substudy (2009) (0)
JACC: Cardiovascular Interventions Top Reviewers 2021. (2022) (0)
TCT-490 Frequency And Impact Of Nuisance Bleeding On Adverse Events After Percutaneous Coronary Intervention: 2-Year Results From The Patterns Of Non-Adherence To Antiplatelet Regimens In Stented Patients (PARIS) Registry (2014) (0)
Late percutaneous recanalization of totally occluded infarct‐related arteries—More than about time (2008) (0)
Whit tent Thrombosis avid (0)
Interrelationship of Thrombin and Platelets: The Protease Activated Receptor‐1 (2012) (0)
Full Issue PDF (2020) (0)
Toward a More Interactive Central Illustration. (2022) (0)
CLOPIDOGREL WITH AND WITHOUT PROTON PUMP INHIBITOR USE: A PARIS REGISTRY ANALYSIS (2014) (0)
CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRACER TRIAL (2016) (0)
CORONARY PERFORATIONS Introduction (2010) (0)
ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND MACE DUE TO STOPPING ONE OR BOTH DRUGS: INSIGHTS FROM THE PARIS REGISTRY (2014) (0)
Anomalous Coronary Arteries (2010) (0)
The impact of left anterior descending coronary artery length on survival following myocardial infarction: To the apex and beyond (2014) (0)
Fractionating Heparin—Reply (2004) (0)
High‐risk coronary anatomy versus high‐risk physiology as outcome predictors in acute coronary syndromes (2014) (0)
Inhibition in Complex Atherosclerotic Lesions Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa (2013) (0)
The challenge of quantifying exceedingly rare occurrences: We can only see what we see (2007) (0)
REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL (2012) (0)
Paradoxical use of angiography with advancing age: insights from an international trial population (2002) (0)
Antiplatelet Therapies Targeting Thrombin Signaling Thrombin Signaling in Platelets (2009) (0)
Peripheral arterial angiography (2010) (0)
PERIPHERAL DIAGNOSTIC CATHETERS (2010) (0)
726 Acute Phase Inflammatory Biomarkers Add Little Predictive Value to Clinical Factors Plus NT-proBNP Among Patients With ST-Segment Elevation Myocardial Infarction: An Apex AMI Trial Substudy (2012) (0)
Therapeutic Advances in Thrombosis: De Caterina/Therapeutic Advances in Thrombosis (2012) (0)
Randomized trial versus registry data—comparing apples and ORCHIDs (2006) (0)
Stent thrombosis through the generations. (2013) (0)
755-3 Improved Prognosis for Heavy Weight Patients Receiving Thrombolysis in Acute Myocardial Infarction — Bigger is Better: Results from GUSTO (1995) (0)
Platelet glycoprotein IIb/IIIa receptor antagonists: fundamental and pharmacological aspects (2008) (0)
Discrepancies Between IVUS and Angiography (2010) (0)
Securing the Future for a Major Academic Cardiovascular Program: Hardwiring a Referral Network and Preparing for a Transition to Value-Based Reimbursement (2020) (0)
Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals. (2019) (0)
The evolution of medical resident training and healthcare delivery: Good riddance to the “July effect” (2023) (0)
Rescue Coronary Intervention for Failed Thrombolysis (2009) (0)
INCIDENCE, PATTERNS AND ASSOCIATIONS BETWEEN DUAL ANTIPLATELET THERAPY CESSATION AND RISK FOR ADVERSE EVENTS IN HIGH-RISK PATIENTS: INSIGHTS FROM THE PARIS REGISTRY (2018) (0)
Ventricular Septal Rupture (2010) (0)
Unstable Angina Trials (2003) (0)
Comprar Interventional Cardiology. 1001 Questions: An Interventional Cardiology Board Review | Debabrata Mukherjee | 9781451112993 | Lippincott Williams & Wilkins (2011) (0)
TCT-211 Incidence and Impact of Dual Antiplatelet Therapy Cessation on Clinical Outcomes in Patients with Renal Dysfunction: Insights from the PARIS Registry. (2016) (0)
One Man's Vacation, Another Man's Stress Test. (2017) (0)
Acute Coronary Syndromes Among Patients with Prior Coronary Artery Bypass Surgery (2022) (0)
P511Incidence and patterns of dual antiplatelet therapy cessation among patients with peripheral arterial disease after percutaneous coronary intervention: insights the PARIS registry (2017) (0)
1063-54 Long-term clopidogrel therapy is particularly beneficial for patients requiring repeat revascularization after an initial percutaneous coronary intervention (2004) (0)
Subject Index Vol. 107, 2007 (2006) (0)
History of heart failure and left ventricular ejection fraction strongly predicts adverse outcomes among patients undergoing contemporary percutaneous coronary intervention: insights from TARGET (2003) (0)
TARGET follow-up study (2002) (0)
3111Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David J. Moliterno,?

David J. Moliterno, is affiliated with the following schools:

David J. Moliterno,'s Academic­Influence.com Rankings

Why Is David J. Moliterno, Influential?

David J. Moliterno,'s Published Works

Published Works

What Schools Are Affiliated With David J. Moliterno,?

David J. Moliterno,'s AcademicInfluence.com Rankings